These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 15690684

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG, Brown SD, Farrell DJ.
    Ann Clin Microbiol Antimicrob; 2008 Jan 11; 7():1. PubMed ID: 18190701
    [Abstract] [Full Text] [Related]

  • 4. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).
    Schito GC, Felmingham D.
    Int J Antimicrob Agents; 2005 Dec 11; 26(6):479-85. PubMed ID: 16289710
    [Abstract] [Full Text] [Related]

  • 5. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
    Jenkins SG, Farrell DJ, Patel M, Lavin BS.
    J Infect; 2005 Dec 11; 51(5):355-63. PubMed ID: 15950288
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.
    Al-Lahham A, Appelbaum PC, van der Linden M, Reinert RR.
    Antimicrob Agents Chemother; 2006 Nov 11; 50(11):3897-900. PubMed ID: 17065627
    [Abstract] [Full Text] [Related]

  • 8. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.
    Wolter N, Smith AM, Low DE, Klugman KP.
    Antimicrob Agents Chemother; 2007 Mar 11; 51(3):1092-5. PubMed ID: 17210764
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
    Felmingham D, Reinert RR, Hirakata Y, Rodloff A.
    J Antimicrob Chemother; 2002 Sep 11; 50 Suppl S1():25-37. PubMed ID: 12239226
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Resistance trends in Moraxella catarrhalis (PROTEKT years 1-3 [1999-2002]).
    Canton R.
    J Chemother; 2004 Dec 11; 16 Suppl 6():63-70. PubMed ID: 15690686
    [No Abstract] [Full Text] [Related]

  • 13. Resistance trends in Staphylococcus aureus (PROTEKT years 1-3 [1999-2002]).
    Jenkins SG.
    J Chemother; 2004 Dec 11; 16 Suppl 6():83-91. PubMed ID: 15690688
    [No Abstract] [Full Text] [Related]

  • 14. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).
    Wierzbowski AK, Karlowsky JA, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2009 Mar 11; 63(3):620-2. PubMed ID: 19151038
    [No Abstract] [Full Text] [Related]

  • 15. Telithromycin-resistant Streptococcus pneumoniae.
    Goldstein F, Vidal B, Kitzis MD.
    Emerg Infect Dis; 2005 Sep 11; 11(9):1489-90. PubMed ID: 16673517
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Induction of telithromycin resistance in Streptococcus pneumoniae.
    Kaieda S, Okitsu N, Yano H, Hosaka Y, Nakano R, Okamoto R, Takahashi H, Inoue M.
    J Antimicrob Chemother; 2003 Oct 11; 52(4):736-7. PubMed ID: 12951334
    [No Abstract] [Full Text] [Related]

  • 19. Introduction to PROTEkT: years 1-3 (1999-2002).
    Harding I.
    J Chemother; 2004 Dec 11; 16 Suppl 6():5-7. PubMed ID: 15690681
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.